The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III trial of gemcitabine and cisplatin versus gemcitabine alone in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) 2: CAPPA-2 study.
Alessandro Morabito
No relevant relationships to disclose
Vittorio Gebbia
No relevant relationships to disclose
Saverio Cinieri
No relevant relationships to disclose
Maria Grazia ViganĂ²
No relevant relationships to disclose
Roberto Bianco
No relevant relationships to disclose
Santi Barbera
No relevant relationships to disclose
Luigi Cavanna
No relevant relationships to disclose
Filippo De Marinis
No relevant relationships to disclose
Vincenzo Montesarchio
No relevant relationships to disclose
Raffaele Costanzo
No relevant relationships to disclose
Claudia Sandomenico
No relevant relationships to disclose
Agnese Montanino
No relevant relationships to disclose
Gianfranco Mancuso
No relevant relationships to disclose
Angelo Nacci
No relevant relationships to disclose
Pasqualina Giordano
No relevant relationships to disclose
Gennaro Daniele
No relevant relationships to disclose
Cesare Gridelli
No relevant relationships to disclose
Gaetano Rocco
No relevant relationships to disclose
Ciro Gallo
No relevant relationships to disclose
Massimo Di Maio
Consultant or Advisory Role - Lilly
Honoraria - Lilly; Roche